Serum-free solutions for cryopreservation of cells

Reports

Abstract

With the development of cell-based assays and therapies, the purity of reagents used to grow and maintain cells has become much more important. In particular, the use of fetal calf serum for culturing cells presents a direct path for potential contamination of cell cultures. In recent years, much research has focused on the development of serum-free culturing systems, not only to alleviate difficulties due to availability and cost of fetal calf serum but also to prevent the transmission of potentially fatal diseases to human patients. Additionally, methods need to be developed for long-term storage of cell stocks that also reduce the risk of exposure to harmful diseases. As most methods employ fetal calf serum in their freezing formulations, solutions that avoid the use of fetal calf serum while providing equivalent or better recovery of cells upon thawing would be ideal. In this study, two vascular cell lines have been cryopreserved as adherent cell populations in two widely used cryoprotectants, dimethyl sulfoxide and 1,2-propanediol, and two vehicle solutions, Euro-Collins and Unisol-cryoprotectant vehicle specifically formulated for the maintenance of cell homeostasis at temperatures below 37° C. The addition of serum to these formulations was also evaluated to determine if its presence provided any additional benefit to the cells during cryopreservation. The results demonstrated that using vehicle solutions designed for lower temperatures produced viable cells that retained cell population viability values up to 75% of unfrozen controls. These results also demonstrated that including serum in the formulation provided no additional benefit to the cells and in some cases actually produced lower cell viability after cryopreservation. In conclusion, the development of solutions designed for low-temperature storage of cells provides a viable alternative to more conventional cryopreservation protocols and eliminates the necessity of including serum in these formulations.

Keywords

Freezing Serum Cytotoxicity Viability 

References

  1. Asher, D. M. The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics. Dev. Biol Stand. 100:103–118; 1999.PubMedGoogle Scholar
  2. Baust, J. M. Molecular mechanisms of cellular demise associated with cryopreservation failure. Cell Preservation Technologies 1:17–32; 2002.CrossRefGoogle Scholar
  3. Baust, J. M.; van Buskirk, R. G.; Baust, J. G. Improved Cryopreservation Outcome is Facilitated by an Intracellular-Type medium and Inhibition of Apoptosis. Journal of the Biomedical Engineering Society 1:206–207; 1999.Google Scholar
  4. Baust, J. M.; Van Buskirk, R.; Baust, J. G. Gene activation of the apoptotic caspase cascade following cryogenic storage. Cell Preservation Technologies 1:63–80; 2002a.CrossRefGoogle Scholar
  5. Baust, J. M.; Van Buskirk, R.; Baust, J. G. Modulation of the cryopreservation cap: elevated survival with reduced dimethyl sulfoxide concentration. Cryobiology 45:97–108; 2002b.PubMedCrossRefGoogle Scholar
  6. Baust, J. M.; Vogel, M. J.; van Buskirk, R. G.; Baust, J. G. A Molecular Basis of Cryopreservation Failure and its Modulation to Improve Cell Survival. Cell Transplantation 10:561–571; 2001.PubMedGoogle Scholar
  7. Bielanski, A.; Bergeron, H.; Lau, P. C.; Devenish, J. Microbial contamination of embryos and semen during long term banking in liquid nitrogen. Cryobiology 46:146–152; 2003.PubMedCrossRefGoogle Scholar
  8. Bradley, R. Bovine spongiform encephalopathy and its relationship to the variant form of Creutzfeldt–Jakob disease. Contrib. Microbiol. 11:146–185; 2004.PubMedCrossRefGoogle Scholar
  9. Brown, P.; Will, R. G.; Bradley, R.; Asher, D. M.; Detwiler, L. Bovine spongiform encephalopathy and variant Creutzfeldt–Jakob disease: background, evolution, and current concerns. Emerg. Infect. Dis. 7:6–16; 2001.PubMedCrossRefGoogle Scholar
  10. Campbell, L. H.; Taylor, M. J.; Brockbank, K. G. M. U.S. Patent #6,596,531 Two stage method for thawing cryopreserved cells; 2003.Google Scholar
  11. Committee for Veterinary Medicinal Products. Guideline on Requirements and Controls Applied to Bovine Serum used in the Production of Immunological Veterinary Medicinal Products. EMEA/CVMP/743-00; 2001.Google Scholar
  12. Croes, E. A. and van Duijn, C. M. Variant Creutzfeldt–Jakob disease. Eur J Epidemiol 18:473–477; 2003.PubMedCrossRefGoogle Scholar
  13. Erickson, G. A.; Bolin, S. R.; Landgraf, J. G. Viral contamination of fetal bovine serum used for tissue culture: risks and concerns. Dev. Biol Stand. 75:173–175; 1991.PubMedGoogle Scholar
  14. Erickson, G. A.; Landgraf, J. G.; Wessman, S. J.; Koski, T. A.; Moss, L. M. Detection and elimination of adventitious agents in continuous cell lines. Dev. Biol Stand. 70:59–66; 1989.PubMedGoogle Scholar
  15. FDA International Conference on Harmonisation. Guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS. Fed. Regist. 63:50244–50249; 1998.Google Scholar
  16. Food and Drug Administration. BSE Estimating Risks for vCJD in Vaccines Using Bovine-Derived Materials. http://www.fda.gov/cber/bse/risk.htm; 2001.
  17. Froud, S. J. The development, benefits and disadvantages of serum-free media. Dev. Biol Stand. 99:157–166; 1999.PubMedGoogle Scholar
  18. Hubálek, Z. Protectants used in the cryopreservation of microorganisms. Cryobiology 46:205–229; 2003.PubMedCrossRefGoogle Scholar
  19. Irani, D. N. and Johnson, R. T. Diagnosis and prevention of bovine spongiform encephalopathy and variant Creutzfeldt–Jakob disease. Annu Rev Med 54:305–319; 2003.PubMedCrossRefGoogle Scholar
  20. Ironside, J. W. and Head, M. W. Variant Creutzfeldt–Jakob disease and its transmission by blood. J Thromb Haemost 1:1479–1486; 2003.PubMedCrossRefGoogle Scholar
  21. Jayme, D. W. An animal origin perspective of common constituents of serum-free medium formulations. Dev. Biol Stand. 99:181–187; 1999.Google Scholar
  22. Jennings, A. Detecting viruses in sera: methods used and their merits. Dev. Biol Stand. 99:51–59; 1999.Google Scholar
  23. Lakey, J. R. T.; Rajotte, R. V.; Fedorow, C. A.; Taylor, M. J. Islet Cryopreservation using Intracellular Preservation Solutions. Cell Transplant 10:583–589; 2001.Google Scholar
  24. Levings, R. L. and Wessman, S. J. Bovine viral diarrhea virus contamination of nutrient serum, cell cultures and viral vaccines. Dev. Biol Stand. 75:177–181; 1991.Google Scholar
  25. Makoschey, B.; van Gelder, P. T.; Keijsers, V.; Goovaerts, D. Bovine viral diarrhoea virus antigen in foetal calf serum batches and consequences of such contamination for vaccine production. Biologicals 31:203–208; 2003.Google Scholar
  26. Merten, O. W. Safety issues of animal products used in serum-free media. Dev. Biol Stand. 99:167–180; 1999.PubMedGoogle Scholar
  27. Nuttall, P. A.; Luther, P. D.; Stott, E. J. Viral contamination of bovine foetal serum and cell cultures. Nature 266:835–837; 1977.PubMedCrossRefGoogle Scholar
  28. Pegg, D. E.; Wusteman, M. C.; Boylan, S. Fractures in cryopreserved elastic arteries: mechanism and prevention. Cryobiology 33:658–659; 1996.Google Scholar
  29. Schlumpf, R.; Morel, Ph.; Loveras, J. J.; Condie, R. M.; Matas, A.; Kurle, J.; Najarian, J. S.; Sutherland, D. E. R. Examination of the Role of the Colloids Hydroxyethylstarch, Dextran, Human Albumin, and Plasma Proteins in a Modified UW Solution. Transplantation Proceedings 23:2362–2365; 1991.PubMedGoogle Scholar
  30. Shiiya, N.; Paul, M.; Bevenuti, C.; Astier, A.; Ferrer, M.-J.; Loisance, D. A. Lactobionate-based Extracellular-type Solution for Donor Heart Preservation. Journal of Heart and Lung Transplantation 12:476–483; 1993.PubMedGoogle Scholar
  31. Southard, J. H.; van Gulik, T. M.; Ametani, M. S.; Vreugdenhil, P. K.; Lindell, S. L.; Pienaar, B. L.; Belzer, F. O. Important Components of the UW Solution. Transplantation 49:251–257; 1990.PubMedCrossRefGoogle Scholar
  32. Sumimoto, R.; Dohi, K.; Urushihara, T.; Jamieson, N. V.; Ito, H.; Sumimoto, K.; Fukuda, Y. An Examination of the Effects of Solutions Containing Histidine and Lactobionate for Heart, Pancreas, and Liver Preservation in the Rat. Transplantation 53:1206–1210; 1992.PubMedCrossRefGoogle Scholar
  33. Taylor, M. J. The Role of pH* and Buffer Capacity in the Recovery of Function of Smooth Muscle cooled to −13 C in Unfrozen Media. Cryobiology 19:585–601; 1982.PubMedCrossRefGoogle Scholar
  34. Taylor, M. J. Biology of cell survival in the cold: The Basis for Biopreservation of Tissues and Organs. In: Baust, J. G. ed. Advances in Biopreservation. Boca Raton: CRC Press; 2004.Google Scholar
  35. Taylor, M. J.; Campbell, L. H.; Rutledge, R. N.; Brockbank, K. G. M. Comparison of Unisol(TM) with EuroCollins Solution as a Vehicle Solution for Cryoprotectants. Transplantation Proceedings 33:677–679; 2001.PubMedCrossRefGoogle Scholar
  36. Taylor, M. J. and Hunt, C. J. A new preservation solution for storage of corneas at low temperatures. Current Eye Research 4:963–973; 1985.PubMedGoogle Scholar
  37. Taylor, M. J. and Pignat, Y. Practical acid dissociation constants, temperature coefficients and buffer capacities for some biological buffers in solutions containing dimethyl sulfoxide between 25 and −12° C. Cryobiology 19:99–109; 1982.PubMedCrossRefGoogle Scholar
  38. Taylor, M. J.; Walter, C. A.; Elford, B. C. The pH-dependent recovery of smooth muscle from storage at −13 C in unfrozen media. Cryobiology 15:452–460; 1978.PubMedCrossRefGoogle Scholar
  39. Trevitt, C. R. and Singh, P. N. Variant Creutzfeldt–Jakob disease: pathology, epidemiology, and public health implications. Am. J Clin. Nutr. 78:651S–656S; 2003.PubMedGoogle Scholar
  40. Ward, H. J.; Head, M. W.; Will, R. G.; Ironside, J. W. Variant Creutzfeldt–Jakob disease. Clin. Lab Med 23:87–108; 2003.PubMedCrossRefGoogle Scholar
  41. Weber, D. J. Biosafety Considerations for Cell-based Therapies. BioPharm International; 2004.Google Scholar
  42. Wessman, S. J. and Levings, R. L. Benefits and risks due to animal serum used in cell culture production. Dev. Biol Stand. 99:3–8; 1999.PubMedGoogle Scholar
  43. Will, R. G.; Ironside, J. W.; Zeidler, M.; Cousens, S. N.; Estibeiro, K.; Alperovitch, A.; Poser, S.; Pocchiari, M.; Hofman, A.; Smith, P. G. A new variant of Creutzfeldt–Jakob disease in the UK. The Lancet 347:921–925; 1996.CrossRefGoogle Scholar
  44. Zabal, O.; Kobrak, A. L.; Lager, I. A.; Schudel, A. A.; Weber, E. L. Contamination of bovine fetal serum with bovine viral diarrhea virus. Rev Argent Microbiol. 32:27–32; 2000.PubMedGoogle Scholar

Copyright information

© The Society for In Vitro Biology 2007

Authors and Affiliations

  1. 1.Cell & Tissues SystemsNorth CharlestonUSA

Personalised recommendations